- Home
- YQ vs CLRB Comparison
YQ vs CLRB Comparison
Compare YQ & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YQ | CLRB |
|---|---|---|
| Founded | 2012 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.7M | 11.1M |
| IPO Year | 2020 | 2008 |
Fundamental Metrics
Financial Performance| Metric | YQ | CLRB |
|---|---|---|
| Price | $2.31 | $2.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 6.3K | ★ 25.6K |
| Earning Date | 06-09-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.63 | $0.23 |
| 52 Week High | $6.45 | $10.19 |
Technical Indicators
Market Signals| Indicator | YQ | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 50.20 |
| Support Level | $1.78 | $2.76 |
| Resistance Level | $2.53 | $3.44 |
| Average True Range (ATR) | 0.21 | 0.19 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 58.11 | 73.85 |
Price Performance
Historical ComparisonAbout YQ 17 Education & Technology Group Inc.
17 Education & Technology Group Inc is an education technology company in China. It offers smart, in-school, teaching and learning SaaS offerings assist students, teachers, schoolmasters and educational authorities across China. It also offer other educational products and services that complement students' in-school learning. Geographically group operates in China.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.